1
|
Allain E, Venzl K, Caron P, Turcotte V, Simonyan D, Gruber M, Le T, Levesque E, Geuillemette C, Vanura K. Circulating hormones and nuclear hormone receptor expression are associated with treatment-free survival in patients with chronic lymphocytic leukemia. Drug Metab Pharmacokinet 2019. [DOI: 10.1016/j.dmpk.2018.09.113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
2
|
Allain EP, Venzl K, Caron P, Turcotte V, Simonyan D, Gruber M, Le T, Lévesque É, Guillemette C, Vanura K. Abstract 5237: Sex-dependent association of circulating sex steroids, pituitary hormones and treatment-free survival in patients with chronic lymphocytic leukemia. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-5237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Chronic lymphocytic leukemia (CLL) is the most frequent adult leukemia in the western world, and is not considered a hormone-regulated cancer but sex is a known risk factor with a significant male/female ratio (2:1) in its incidence with male patients more frequently developing progressive disease. We hypothesized that variable hormonal exposure may have a sexually dimorphic effect on CLL progression. However, a detailed evaluation of sex steroids and pituitary hormones in CLL patients is still lacking. In 156 CLL patients, we quantitatively profiled 15 circulating sex steroids (androgens, estrogens and progesterone) by sensitive and specific mass spectrometry and two pituitary hormones (luteinizing hormone (LH) and follicular secreting hormone (FSH)) by immunoassay. Data were analyzed separately by sex and in relation to treatment-free survival (TFS). Univariate and multivariate analyses of TFS were performed using Cox's proportional hazard model with hormone levels as continuous variables. Median age of CLL patients was 59.8 and 62.9 years for men and postmenopausal women, respectively. Common CLL prognostic markers had very similar frequencies between male and female cases. Median TFS was shorter for male patients than for women (80.7 vs. 135.0 months, P=0.033). Circulating profiles of hormones in CLL patients were significantly different from those of healthy donors whereas male cases had higher steroid levels than female patients. In male CLL cases, sex steroid levels were not significantly associated with TFS; however, higher LH levels were associated with shorter TFS in multivariate analyses with an adjusted hazard ratio (HRadj) of 2.11 (P = 0.004). In female CLL cases, high levels of potent androgens testosterone, dihydrotestosterone (DHT) and the sum of methoxy estrogens were significantly associated with improved TFS with HRadj values of 0.24 (P =0.007), 0.54 (P=0.023) and 0.31 (P =0.034), respectively. This study is the first to establish a link between outcome of CLL patients and circulating sex steroid and pituitary hormones, revealing a sex-specific hormonal imbalance associated with disease progression. This work was supported by a Canadian Institutes of Health Research grant to CG. EPA holds scholarships from Université Laval foundation - Leadership and sustainable development award and CHU de Québec foundation - Fernand Labrie excellence award.
Citation Format: Eric P. Allain, Karin Venzl, Patrick Caron, Véronique Turcotte, David Simonyan, Michaela Gruber, Trang Le, Éric Lévesque, Chantal Guillemette, Katrina Vanura. Sex-dependent association of circulating sex steroids, pituitary hormones and treatment-free survival in patients with chronic lymphocytic leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5237.
Collapse
Affiliation(s)
- Eric P. Allain
- 1Pharmacogenomics laboratory, Centre Hospitalier Universitaire de Québec (CHU) Research Center, Université Laval., Québec, Quebec, Canada
| | - Karin Venzl
- 2Division of Hematology and Hemostaseology, Department of Medecine I, Medical University of Vienna., Vienna, Austria
| | - Patrick Caron
- 1Pharmacogenomics laboratory, Centre Hospitalier Universitaire de Québec (CHU) Research Center, Université Laval., Québec, Quebec, Canada
| | - Véronique Turcotte
- 1Pharmacogenomics laboratory, Centre Hospitalier Universitaire de Québec (CHU) Research Center, Université Laval., Québec, Quebec, Canada
| | - David Simonyan
- 3Statistial and Clinical Research Platform, CHU de Québec Research Center., Québec, Quebec, Canada
| | - Michaela Gruber
- 2Division of Hematology and Hemostaseology, Department of Medecine I, Medical University of Vienna., Vienna, Austria
| | - Trang Le
- 2Division of Hematology and Hemostaseology, Department of Medecine I, Medical University of Vienna., Vienna, Austria
| | - Éric Lévesque
- 1Pharmacogenomics laboratory, Centre Hospitalier Universitaire de Québec (CHU) Research Center, Université Laval., Québec, Quebec, Canada
| | - Chantal Guillemette
- 1Pharmacogenomics laboratory, Centre Hospitalier Universitaire de Québec (CHU) Research Center, Université Laval., Québec, Quebec, Canada
| | - Katrina Vanura
- 2Division of Hematology and Hemostaseology, Department of Medecine I, Medical University of Vienna., Vienna, Austria
| |
Collapse
|
3
|
Allain EP, Venzl K, Caron P, Turcotte V, Simonyan D, Gruber M, Le T, Lévesque E, Guillemette C, Vanura K. Sex-dependent association of circulating sex steroids and pituitary hormones with treatment-free survival in chronic lymphocytic leukemia patients. Ann Hematol 2018; 97:1649-1661. [PMID: 29781039 PMCID: PMC6097785 DOI: 10.1007/s00277-018-3356-z] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Accepted: 04/28/2018] [Indexed: 02/06/2023]
Abstract
Chronic lymphocytic leukemia (CLL) is not considered a hormone-regulated cancer although sex is a recognized risk factor with men more frequently diagnosed and developing progressive disease. We hypothesized that variable hormonal exposure may have a sexually dimorphic influence on treatment-free survival (TFS). In 156 CLL cases, we quantitatively profiled 29 circulating steroids (progesterone, adrenal precursors, androgens, estrogens, and catechol estrogens) as well as luteinizing hormone (LH) and follicle-stimulating hormone. Median TFS was shorter for men than that for women (80.7 vs. 135.0 months, P = 0.033). Circulating hormone profiles in CLL patients were significantly different from those of healthy donors. In male CLL cases, higher LH levels were associated with shorter TFS (adjusted hazard ratio (HRadj) 2.11; P = 0.004). In female CLL cases, high levels of the potent androgens testosterone and dihydrotestosterone and the sum of methoxy estrogens were associated with an improved TFS with HRadj values of 0.24 (P = 0.007), 0.54 (P = 0.023), and 0.31 (P = 0.034), respectively. Reduced TFS was observed for women with CLL exhibiting high expression of the steroid-inactivating UGT2B17 enzyme. This study is the first to establish a link between the outcome of CLL patients, sex steroids, and pituitary hormones, revealing a sex-specific hormonal imbalance associated with disease progression.
Collapse
Affiliation(s)
- Eric P Allain
- Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, R4701.5, 2705 Blvd. Laurier, Québec, G1V 4G2, Canada
| | - Karin Venzl
- Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
| | - Patrick Caron
- Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, R4701.5, 2705 Blvd. Laurier, Québec, G1V 4G2, Canada
| | - Véronique Turcotte
- Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, R4701.5, 2705 Blvd. Laurier, Québec, G1V 4G2, Canada
| | - David Simonyan
- Statistical and Clinical Research Platform, CHU de Québec Research Center, Québec, Canada
| | - Michaela Gruber
- Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
| | - Trang Le
- Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
| | - Eric Lévesque
- CHU de Québec Research Centre, Faculty of Medicine, Laval University, Québec, Canada
| | - Chantal Guillemette
- Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, R4701.5, 2705 Blvd. Laurier, Québec, G1V 4G2, Canada. .,Canada Research Chair in Pharmacogenomics, Québec, Canada.
| | - Katrina Vanura
- Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
| |
Collapse
|